Regenerative medicine offers a

transformative approach to healthcare,

with the potential to not only treat, but cure disease. The therapeutic application of cells, or cell-based therapy, forms a fundamental part of this landscape and already has global revenues of over US$1 billion.

SAKARTA is an exciting start-up with an objective to transform the Regenerative Medicine field through the delivery of automated systems that reduce both production bosts and product variability, thus enabling cell and gene therapies to become a mainstream component of an advanced healthcare system.

Regenerative medicine offers a transformative approach to healthcare, with the potential to not only treat, but cure disease. The therapeutic application of cells, or cell-based therapy, forms a fundamental part of this landscape and already has global revenues of over US$1 billion.

However, Cell Therapy manufacture is extremely challenging; the cells have to be produced according to Good Manufacturing Practice (GMP) within a highly specialised facility and require weeks of careful nurturing and monitoring by highly qualified staff.

The variable nature of the starting material (cells) and manual labour means that failure rates are high. Hence, cell therapies are extremely expensive, with over 60% of the cost attributable to manufacturing.

All experts in the sector agree that the way forward for cell therapies is to automate their production. This will reduce the need for trained staff and reduce product variability, thus lowering costs whilst maintaining profit margin.

SAKARTA Ltd is building automated solutions for cell therapy (and stem cell) manufacture. Together with our key collaborators in England and Japan, we are developing a robotic platform to deliver novel treatments for degenerative diseases.

The Intelligent Cell Processing (ICP) system is our flagship project which will deliver an automated manufacturing platform for adherent cells, meets full GMP compliance, in keeping with customer and full regulatory demands.